Parenteral Manual


Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
HERCEPTIN®, rhuMAbHER2, NSC #688097
Monoclonal Antibody (humanized)
Original Date: 
August 2005
Revised Date: 
  • Approved for use in the treatment of patients with metastatic breast cancer whose tumors substantially over express the HER2 protein
  • Investigational in children (Phase II) as adjunctive immunotherapy for metastatic osteosarcoma over expressing HER2
Reconstitution and Stability: 
  • Available as a freeze-dried powder at 440 mg per vial
  • Reconstitute with 20 mL of Bacteriostatic Water for Injection (BWFI), supplied, to give a final concentration of 21 mg/mL.  Swirl gently.  DO NOT SHAKE SOLUTION.
  • Reconstituted solution should be clear to slightly opalescent, and colorless to pale yellow
  • Solution reconstituted with BWFI is stable for 28 days in the refrigerator
  • DO NOT FREEZE reconstituted solution
  • Dilute further in 250 mL NS to administer IV.  Mix by inverting bag gently to avoid foaming.
  • Diluted solutions stable 24 hours at room temperture.  Refrigerate to avoid bacterial contamination.

- Solutions Compatibe: NS. DO NOT USE D5W.

- No other compatibility known.  Run in dedicated line.


(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

IV Push NO
IV Intermittent Infusion


  • Intermittent infusion is mandatory.  Run infusion over 90 minutes until tolerance is known.  If well tolerated (absence of fever, chills, rigors, nausea, vomiting, headache, rash, asthenia, pain at tumor site), infusion time for subsequent infusions can be decreased to 60 and then 30 minutes.
IV Continuous Infusion NO

(For neonatal dosages, refer to Neonatal IV Drug Manual.)

  • For COG protocol AOST0121, 4 mg/kg week 1, then 2 mg/kg weekly for a further 33 weeks (total of 34 weekly doses)
  • Give prior to the start of chemotherapy

** Dosage may differ according to protocol

Potential hazards of parenteral administration: 
  • Common: fever, chills, rigors, nausea, vomiting, headache, rash, asthenia, pain at tumor site, diarrhea
  • Occasional: flu-like syndrome - paresthesias, bone pain, arthralgias
  • Rare: hypotension; anaphylaxis; ARDS; bronchospasm; dyspnea; death from allergic, pulmonary, or infusion reactions

- Treatment for unusual side effects are available through the study chair identified on the front of the protocol and/or pharmacy

  • Infusion requires 1:1 nursing, with vital signs (BP, HR, RR, TºC) monitoring every 15 minutes during infusion and for 60 minutes post-infusion
  • Have anaphylaxis kit available at bedside
  • Premedication with acetaminophen, antihistamine, or steroid may be required depending on tolerance

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.